Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.02009 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Ruinuo Jia und 37 weiteren Autor:innen. Beteiligte Einrichtung: Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The F…. Hauptthemen laut MEDLINE: Capecitabine, Fluorouracil, Cisplatin, Esophageal Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS Patients were randomly assigned to receive two cycles of capecitabine, XELOX, or PF along with concurrent intensity-modulated radiation therapy. Patients in each arm were again randomly assigned to receive two cycles of consolidation chemotherapy or not. The primary end points were 2-year overall survival (OS) rate and incidence of grade ≥3 adverse events (AEs). RESULTS A total of 246 patients were randomly assigned into the capecitabine (n = 80), XELOX (n = 85), and PF (n = 81) arms. In capecitabine, XELOX, and PF arms, the 2-year OS rate was 75%, 66.7%, and 70.9% (capecitabine v PF: hazard ratio [HR], 0.91 [95% CI, 0.61 to 1.35]; nominal P = .637; XELOX v PF: 0.86 [95% CI, 0.58 to 1.27]; P = .444); the median OS was 40.9 (95% CI, 34.4 to 49.9), 41.9 (95% CI, 28.6 to 52.1), and 35.4 (95% CI, 30.4 to 45.4) months. The incidence of grade ≥3 AEs during the entire treatment was 28.8%, 36.5%, and 45.7%, respectively. Comparing the consolidation chemotherapy with the nonconsolidation chemotherapy groups, the median OS was 41.9 (95% CI, 34.6 to 52.8) versus 36.9 (95% CI, 28.5 to 44) months (HR, 0.71 [95% CI, 0.52 to 0.99]; nominal P = .0403). CONCLUSION Capecitabine or XELOX did not significantly improve the 2-year OS rate over PF in DCRT for inoperable locally advanced ESCC. Capecitabine showed a lower incidence of grade ≥3 AEs than PF did.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine) of Henan Unive…
- Department of Radiation Oncology, Anyang Tumor Hospital, The Affiliated Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Henan Medical Key Laboratory of Precise Prevention an…
- Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
- Department of Oncology, Xinxiang Central Hospital, Xinxiang, China.
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Kaifeng Central Hospital, Kaifeng, China.
ORCID-Profile: Ruinuo Jia, Yingjuan Zheng, Qiming Wang, Shegan Gao
Zitieren
APA
Jia, R., Shan, T., Zheng, A., Zhang, Y., Lu, P., Zhang, G., Wang, F., Xu, Z., Zheng, G., Tang, D., Zhang, W., Li, W., Li, R., Guo, Y., Liu, L., Luo, X., Zheng, Y., Chang, Z., Wang, Q., …, & Gao, S. (2024). Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02009
Vancouver
Jia R, Shan T, Zheng A, Zhang Y, Lu P, Zhang G, et al. Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02009
BibTeX
@article{Jia2024,
author = {Jia, Ruinuo and Shan, Tanyou and Zheng, Anping and Zhang, Yaowen and Lu, Ping and Zhang, Guifang and Wang, Feng and Xu, Zhiqiao and Zheng, Guobao and Tang, Dongxia and Zhang, Weiguo and Li, Wanying and Li, Ruonan and Guo, Yibo and Liu, Lina and Luo, Xiaoyong and Zheng, Yingjuan and Chang, Zhiwei and Wang, Qiming and Wang, Xinshuai and Yuan, Xiaozhi and Kong, Guoqiang and Li, Shuoguo and Yang, Ruina and Zhou, Dan and Ren, Jing and Yin, Weijiao and Li, Jingxia and Zhang, Junqian and Wang, Ziqi and Sheng, Manxi and Xu, Bingyi and Li, Liuyan and Liu, Xiaoyi and Lu, Zhihao and Wan, Lixin and Zhou, Fuyou and Gao, Shegan},
title = {Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.02009}
}
EUVIMED